6-Thio-2'-Deoxyguanosine

DRUG2 trials

Sponsors

Maia Biotechnology

Conditions

Carcinoma, Non-Small -Cell LungCarcinoma, Non-Small-Cell Lung

Phase 2

THIO Sequenced With Cemiplimab in Advanced NSCLC

RecruitingNCT05208944

Maia BiotechnologyCarcinoma, Non-Small-Cell Lung

Start: 2022-06-08End: 2027-12-31Target: 227Updated: 2026-01-20

Phase 3

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

RecruitingNCT06908304

Maia BiotechnologyCarcinoma, Non-Small -Cell Lung

Start: 2025-12-08End: 2027-12-31Target: 300Updated: 2026-01-12

Related Papers

Abstract B015: A Phase 2 Study of Ateganosine (THIO) in Combination with Immune Checkpoint Inhibitor (ICI) in Patients with Advanced NSCLC Resistant to Prior ICI and Chemotherapy: THIO-101 Trial in Progress

Molecular Cancer Therapeutics2025-10-22

Phase 2 study of telomere-targeting agent THIO sequenced with cemiplimab in third-line immune checkpoint inhibitor–resistant advanced NSCLC: Evaluation of overall survival (OS).

Journal of Clinical Oncology2025-05-28

A Phosphatidyl Conjugated Telomerase-Dependent Telomere-Targeting Nucleoside Demonstrates Colorectal Cancer Direct Killing and Immune Signaling

Biomolecules2024-12-18

A phase 2, multicenter, open-label, dose-optimization study evaluating telomere-targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Updated results.

Journal of Clinical Oncology2024-06-011 citations

Abstract CT050: A phase 2, multi-center, open-label, dose-finding study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC

Cancer Research2023-04-14